Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and ...

Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Resmed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market ...

EBR Systems, backed by investors such as HESTA, Hostplus and private equity veteran Mark Carnegie, can start selling its technology within months.

ResMed Inc. closed 19.96% below its 52-week high of $263.05, which the company achieved on January 30th.

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

The risk of both all-cause deaths and those caused by cardiovascular conditions in OSA patients is significantly reduced with the use of CPAP therapy.

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and cloud-connected software for the healthcare sector. With a market cap of $33 ...